Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(12):998-1000; doi:10.1093/jnci/91.12.998
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 12, 998-1000, June 16, 1999
© 1999 Oxford University Press

NEWS

Second Line Therapies Move to the Forefront in Colorectal Cancer

Mike Miller

After more than 30 years, a new standard of treatment for metastatic colorectal cancer may be close at hand, according to experts at the annual meeting of the American Society of Clinical Oncology in Atlanta, last month.

Two new drugs, CPT-11 (also known as irinotecan or CamptosarTM) and oxaliplatin (Eloxatine) — both of which have shown promise in a number of earlier studies — now appear to substantially improve the time to tumor progression when used in combination with the existing standard of care. Since the 1960s, patients with advanced colorectal cancer have received 5-fluorouracil, . . . [Full Text of this Article]

Multicenter Trial

Best Therapy?

Hepatic Pump


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?